Athersys, Inc. (ATHX) News
Filter ATHX News Items
ATHX News Results
|Loading, please wait...|
ATHX News Highlights
- For ATHX, its 30 day story count is now at 2.
- Over the past 12 days, the trend for ATHX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ATHX are CELL.
Latest ATHX News From Around the Web
Below are the latest news stories about ATHERSYS INC that investors may wish to consider to help them evaluate ATHX as an investment opportunity.
Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation
CLEVELAND, September 06, 2023--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that Dr. Samuel Tingle, a surgeon and PhD candidate at Newcastle University in Newcastle upon Tyne, England, has received grant funding from the UK Research and Innovation’s Medical Research Council to explore the potential use of Athersys’ MultiStem cellular therapy during machine perfusion prior to kidney t
Unraveling the Valuation and Financial Health of Athersys Inc
Applied Materials (AMAT) stock is climbing higher on Friday after getting new price targets following its latest earnings report.
Investors in Chinese stocks are noticing a trend today as many major players in the market are seeing their shares fall on Friday.
Athersys (ATHX) stock is falling on Friday after the biotechnology company announced a $3.5 million public stock offering.
We're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday!
CLEVELAND, August 18, 2023--Athersys, Inc. (Nasdaq: ATHX), today announced the pricing of its "reasonable best efforts" public offering of 10,937,500 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.32 per share. The Company further agreed to issue to the investors Series A Warrants to purchase up to an aggregate of 10,937,500 shares of common stock and Series B Warrants to purchase up to an aggregate of 10,937,500 shares of common stock. The Series
CLEVELAND, August 16, 2023--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update.
In this article, we will be taking a look at the 20 states with the longest life expectancy in America. If you want to skip our detailed analysis of companies that are working on improving life expectancy, you can go directly to see the 5 States With The Longest Life Expectancy In America. Life Expectancy […]
CLEVELAND, August 11, 2023--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema Mayhugh, PhD to its Board of Directors. Dr. Mayhugh is an executive with more than 20 years of experience in healthcare consulting, industry, academic and hospital settings.